2013/2014 ASCO-CAP指南下FISH检测HER2不确定乳腺癌的ERBB2/HER2状态评估
该研究回顾性分析METABRIC队列1980例浸润性乳腺癌(1915例完整评估)及BCIRG-005试验中100例FISH HER2不确定和100例FISH阴性乳腺癌,评估2013/2014 ASCO-CAP指南推荐的17号染色体替代对照探针(TP53、D17S122、SMS、RARA、TOP2A)用于HER2 FISH检测时,因对照位点杂合性缺失导致假阳性比率(HER2/替代对照≥2.0)及错误分类的风险,结论认为不加选择地使用替代对照探针可能因未识别的杂合性缺失导致HER2状态假阳性解读。
要点
- 17号染色体短臂特定对照位点杂合性缺失在HER2扩增及非扩增乳腺癌中均常见。
- 使用这些替代对照探针计算HER2 FISH比率,在HER2不确定及非扩增乳腺癌中产生高比例假阳性比率(≥2.0)。
- 错误分类不仅见于ASCO-CAP不确定病例,也见于平均HER2拷贝数<4.0的乳腺癌。
核心结论
- 不加选择地使用替代对照探针计算HER2 FISH比率,可能因未识别的1个或多个替代对照基因组位点杂合性缺失及错误的HER2比率判定,导致HER2状态假阳性解读。
研究设计与样本
- 回顾性评估2013/2014 ASCO-CAP指南推荐的17号染色体p臂和q臂替代对照基因组位点(TP53、D17S122、SMS、RARA、TOP2A)在乳腺癌中的应用。
- 使用METABRIC国际浸润性乳腺癌队列数据库1980例患者数据,其中1915例完成完整评估。
- 分析来自BCIRG-005试验的100例FISH HER2不确定乳腺癌和100例FISH阴性对照乳腺癌。
主要发现
- 杂合性缺失,尤其特定p臂位点,在HER2扩增和HER2非扩增乳腺癌中均常见。
- 在HER2不确定及HER2非扩增乳腺癌中,使用这些区域替代对照探针导致高比例的假阳性比率(HER2/替代对照比值≥2.0),源于比值分母所用对照p臂基因组位点的杂合性缺失。
- 错误分类不仅见于ASCO-CAP不确定状态乳腺癌,也见于使用替代对照探针时平均每肿瘤细胞HER2拷贝数少于4.0的乳腺癌。
关键数值与推荐
- 2013/2014 ASCO-CAP指南将FISH HER2不确定定义为平均每肿瘤细胞HER2拷贝数≥4-6且HER2/CEP17比值<2.0,需用替代对照探针评估以判定阴性或阳性。
- 约4%至12%的浸润性乳腺癌根据FISH被判定为HER2不确定。
- 假阳性比率定义为HER2与替代对照比值≥2.0。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The 2013/2014 American Society of Clinical Oncology and College of American Pathologists (ASCO-CAP) guidelines for HER2 testing by fluorescence in situ hybridization (FISH) designated an "equivocal" category (average HER2 copies per tumor cell ≥4-6 with HER2/CEP17 ratio <2.0) to be resolved as negative or positive by assessments with alternative control probes. Approximately 4% to 12% of all invasive breast cancers are characterized as HER2-equivocal based on FISH. OBJECTIVE: To evaluate the following hypotheses: (1) genetic loci used as alternative controls are heterozygously deleted in a substantial proportion of breast cancers; (2) use of these loci for assessment of HER2 by FISH leads to false-positive assessments; and (3) these HER2 false-positive breast cancer patients have outcomes that do not differ from clinical outcomes for patients with HER2-negative breast cancer. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively assessed the use of chromosome 17 p-arm and q-arm alternative control genomic sites (TP53, D17S122, SMS, RARA, TOP2A), as recommended by the 2013/2014 ASCO-CAP guidelines for HER2 testing, in patients whose data were available through Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and whose tissues were available through the Breast Cancer International Research Group clinical trials. We used data from an international cohort database of invasive breast cancers (1980 participants) and international clinical trial of adjuvant chemotherapy in invasive, node-positive breast cancer patients. MAIN OUTCOMES AND MEASURES: The primary objectives were to (1) assess frequency of heterozygous deletions in chromosome 17 genomic sites used as FISH internal controls for evaluation of HER2 status among HER2-equivocal cancers; (2) characterize impact of using deleted sites for determination of HER2-to-internal-control-gene ratios; (3) assess HER2 protein expression in each subgroup; and (4) compare clinical outcomes for each subgroup. RESULTS: Of the 1980 patients in METABRIC,1915 patients were fully evaluated. In addition, 100 HER2-equivocal breast cancers by FISH and 100 comparator FISH-negative breast cancers from the BCIRG-005 trial were analyzed. Heterozygous deletions, particularly in specific p-arm sites, were common in both HER2-amplified and HER2-not-amplified breast cancers. Use of alternative control probes from these regions to assess HER2 by FISH in HER2-equivocal as well as HER2-not-amplified breast cancers resulted in high rates of false-positive ratios (HER2-to-alternative control ratio ≥2.0) owing to heterozygous deletions of control p-arm genomic sites used in ratio denominators. Misclassification of HER2 status was observed not only in breast cancers with ASCO-CAP equivocal status but also in breast cancers with an average of fewer than 4.0 HER2 copies per tumor cell when using alternative control probes. CONCLUSIONS AND RELEVANCE: The indiscriminate use of alternative control probes to calculate HER2 FISH ratios in HER2-equivocal breast cancers may lead to false-positive interpretations of HER2 status resulting from unrecognized heterozygous deletions in 1 or more of these alternative control genomic sites and incorrect HER2 ratio determinations.
引用
- Press MF, Seoane JA, Curtis C, et al. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. JAMA Oncol. 2019. PMID: 30520947. doi:10.1001/jamaoncol.2018.6012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。